On 24 May 2018
Glaxosmithkline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 24 May 2018, inter alia, to consider, approval of audited financial results (Standalone & Consolidated) for the quarter / year ended March 31, 2018 and to recommend dividend, if any, on the equity shares of the Company.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
